VANI - Latest News
Vivani Medical, Inc. (VANI), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $120.7M. Beta to the broader market is 3.28.
The article list below shows the most recent VANI headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent VANI Headlines
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com - Aug 13, 2026
All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide impl
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
globenewswire.com - Aug 6, 2026
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
marketbeat.com - Jul 15, 2026
Vivani Medical NASDAQ: VANI said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agre
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
globenewswire.com - Jul 14, 2026
ALAMEDA, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc.
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
globenewswire.com - Jul 7, 2026
ALAMEDA, Calif. , July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc.
How News Affects VANI Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track VANI's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked VANI news questions
- What is the latest VANI news headline?
- The most recent VANI headline (Aug 13, 2026) is "Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the VANI news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What VANI news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual VANI options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.